S. Davidson

Phase I study of everolimus, cetuximab and irinotecan as second-line therapy in metastatic colorectal cancer.

J. Hecht, Sunil Sharma, C. Garrett, 2015, Anticancer research.

Phase I study of RAD001 (everolimus), cetuximab, and irinotecan as second-line therapy in metastatic colorectal cancer (mCRC).

C. Garrett, T. Reid, J. Hecht, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Avasopasem manganese (GC4419) protects against cisplatin-induced chronic kidney disease: An exploratory analysis of renal metrics from a randomized phase 2b clinical trial in head and neck cancer patients

J. Buatti, J. Holmlund, D. Spitz, 2023, Redox biology.

An open-label phase II clinical trial of the RXR agonist IRX4204 in taxane-resistant, castration-resistant metastatic prostate cancer (CRPC).

F. Kabbinavar, M. Rettig, R. Chandraratna, 2014 .